Levemir (insulin detemir rDNA origin) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 62 Diseases   26 Trials   26 Trials   826 News 


«12345678910»
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Trial completion date, Trial primary completion date:  IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) -  Jun 11, 2020   
    P=N/A,  N=240, Active, not recruiting, 
    Further research should be made in order to determine if GLP-1 agonists should be contraindicated in patients with severe hypertriglyceridemia, as both increase risk for pancreatitis. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Byetta (exenatide) / AstraZeneca
    Trial completion, Enrollment change:  New Onset Type 1 Diabetes: Role of Exenatide (clinicaltrials.gov) -  Jun 4, 2020   
    P4,  N=14, Completed, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Completed | N=20 --> 14
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    New P4 trial:  Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) -  Jun 3, 2020   
    P4,  N=260, Recruiting, 
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    [VIRTUAL] Molecular and Biological Properties of Insulin Icodec, a New Insulin Analog Designed to Give a Long Half-Life Suitable for Once-Weekly Dosing () -  May 18, 2020 - Abstract #ADA2020ADA_3512;    
    To attain such a long half-life, the insulin molecule was modified to achieve an albumin-bound circulating depot of icodec which acts just as human insulin (HI) but is more slowly cleared.Addition of a C20 fatty diacid containing side chain at B29K via a hydrophilic linker imparts strong but reversible albumin binding (10x that of insulin detemir)...The in vitro mitogenic effect of icodec in primary human mammary cells (HMEC), as well as in mammary and colon carcinoma cells (MCF-7 and COLO 205) was found to be low relative to that of HI.In conclusion, icodec is a new insulin analog designed to achieve a slowly cleared, albumin-bound circulating depot which results in a long half-life suited for once weekly injections, covering the basal insulin requirements for a full week. *Insulin icodec (proposed INN).
  • ||||||||||  metformin / Generic mfg.
    Trial completion date, Trial primary completion date:  FIMMET201501: MeDiGes Study: Metformine Use in Gestational Diabetes (clinicaltrials.gov) -  May 14, 2020   
    P3,  N=200, Active, not recruiting, 
    Proper safety measures and mandatory nurse education about administration of insulin were implemented to prevent future occurrences. Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Feb 2020 --> May 2020
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Review, Journal:  Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. (Pubmed Central) -  May 9, 2020   
    These advantages can lead to decreased healthcare resource utilization and cost. With this collective knowledge, healthcare providers and payers can make educated and well-informed decisions when determining which treatment regimen best meets the needs of each individual patient.Funding: Sanofi US, Inc.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Journal:  Determining the effects of insulin Detemir on endogenous secretion of insulin. (Pubmed Central) -  May 9, 2020   
    The results show the model captures glucose-insulin dynamics in pre-diabetic post-surgical patients, and insulin Detemir may be useful to support individuals with pre-diabetes in reducing blood glucose levels. Tests with higher doses, need to be carried out to verify these results over a greater range of patients.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Enrollment closed, HEOR:  Determin: Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy (clinicaltrials.gov) -  Apr 15, 2020   
    P4,  N=216, Active, not recruiting, 
    Thus, we prefer and suggest this beneficial method (using Novo-rapid and Levemir Insulin) to reach therapeutic goals. Recruiting --> Active, not recruiting
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] INSULIN PRICES IN CANADA, SAUDI ARABIA, AND THE US. () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1819;    
    The indexed price for insulin glulisine 100 units/ml vial was 42.2 in Saudi Arabia, 100.0 in Canada, and 548.4 in the US; insulin lispro 100 units/ml pen was 49.6 in Saudi Arabia, 100.0 in Canada, and 697.0 in the US; insulin Glargine 100 units/ml pen was 41.6 in Saudi Arabia, 100.0 in Canada, and 224.8 in the US; insulin detemir 100 units/ml pen was 35.0 in Saudi Arabia, 100.0 in Canada, and 263.5 in the US; Insulin degludec 100 units/ml pen was 63.8 in Saudi Arabia, 100.0 in Canada, and 380.6 in the US; insulin degludec 200 units/ml pen was 64.7 in Saudi Arabia, 100.0 in Canada, and 385.1 in the US. Prices of insulin products on January 1, 2020, were over 4 times higher in the US than in Canada, and over 8 times higher in the US than in Saudi Arabia.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    PK/PD data, Journal:  A subcutaneous insulin pharmacokinetic model for insulin Detemir. (Pubmed Central) -  Feb 24, 2020   
    The pharmacokinetic curves are suitable for model-based control and general enough for use. While there are limitations in the studies used for validation that prevent a more complete understanding, the results provide an effective first model and justify the design and implementation of further, more precise human trials.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Clinical, Journal:  Costs associated with long-acting insulin analogues in patients with diabetes. (Pubmed Central) -  Feb 16, 2020   
    Despite higher drug costs, the real-world overall medical costs of LAIAs are not significantly different from those of NPH in patients with diabetes. The findings may be helpful for formulary decision making for patients with diabetes in a cost-constrained environment.
  • ||||||||||  metformin / Generic mfg., Tresiba (insulin degludec) / Novo Nordisk
    Approach to a Potential Liver Transplant Candidate with Insulin Antibody-Mediated Severe Insulin Resistance (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_2679;    
    This can place patients at high risk for infection, poor wound healing and most importantly prohibit liver transplantation. Immunosuppressant therapy and plasmapheresis may drastically lower insulin antibodies and improve glycemic control, however, it will increase the risk of infection.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Management of Hyperglycemia in an Adult Patient with Glycogen Storage Disease Type 1b (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_2673;    
    The pathogenesis may be related to effects of chronic pancreatitis or metabolic syndrome. Treatment of hyperglycemia in patients with GSD1b is challenging given the heightened risk of fasting hypoglycemia.
  • ||||||||||  Janumet (metformin + sitagliptin) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    A Case of Opdivo Induced Type 1 Diabetes (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_1935;    
    At discharge she was continued on 22 units of levemir, a humalog sliding scale, and Janumet...Yervoy also carries a risk of further endocrine disorders, including increased risk of hypophysitis...It was crucial in this patient to identify this side effect of Opdivo, as it helped to prevent further episodes of DKA. Careful review of recent medication changes helped identify this uncommon complication of Opdivo and prompted a timely change in her diabetes care regimen.
  • ||||||||||  metformin / Generic mfg.
    Trial primary completion date:  FIMMET201501: MeDiGes Study: Metformine Use in Gestational Diabetes (clinicaltrials.gov) -  Jan 30, 2020   
    P3,  N=200, Active, not recruiting, 
    Furthermore, CGMS can be used to evaluate glycemic control in patients with DM when treated with various glucocorticoids. Trial primary completion date: Jun 2019 --> Feb 2020
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Journal:  Long-Acting Basal Insulins: A Review of the More Recently Approved Agents. (Pubmed Central) -  Jan 18, 2020   
    Both insulin glargine U-300 and insulin degludec have been compared with insulin glargine U-100 and have demonstrated longer durations of action, as well as lower rates of hypoglycemia. This review discusses the Food and Drug Administration-approved long-acting insulins with a focus on recently approved agents and their efficacy and safety compared with the first long-acting basal insulins.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Preclinical, Journal:  Effects of noopept on cognitive functions and pubertal process in rats with diabetes. (Pubmed Central) -  Oct 29, 2019   
    These trials, the first to systematically collect data on ketosis in pediatric patients with T1D, demonstrate the potential of degludec/IDegAsp to reduce rates of metabolic decompensation, compared with IDet. Noopept may have positive effect in treatment of pubertal diabetes.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes. (Pubmed Central) -  Oct 29, 2019   
    Despite improving beta-cell function, insulin resistance and glucagonemia, short-term IIT does not change GLP-1 secretion and decreases the GIP response to an oral glucose challenge in early type 2 diabetes. Thus, the beneficial impact of this therapy on glucose homeostasis is not attributable to its effects on incretin secretion.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Clinical, Journal, HEOR:  Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. (Pubmed Central) -  Sep 25, 2019   
    Degludec provides appreciable annual cost savings compared with IDet in children and adolescents with T1D in a UK setting. While a cost-effectiveness analysis could incorporate the health impact of treatment complications better than the present cost analysis, the strong generalizability of the data from this study suggests that degludec can help healthcare providers to maximize health outcomes despite increasingly stringent budgets.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Insulins for type 2 diabetes. (Pubmed Central) -  Aug 6, 2019   
    The case report demonstrated a good example of how clinicians deal with the rare but important questions of hypersensitivity reactions to insulin analogue. No abstract available